Medprin Regenerative Medical Technologies Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yuyu Yuan

Chief Executive Officer (CEO)

CN¥773.7k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	16.6%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Looks Just Right With A 38% Price Jump

May 08

CEO

Yuyu Yuan (43 yo)

no data

Permanencia

CN¥773,700

Compensación

Ms. Yuyu Yuan serves as Chairman of the Board and General Manager at Medprin Regenerative Medical Technologies Co., Ltd.

Medprin Regenerative Medical Technologies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Medprin Regenerative Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Medprin Regenerative Medical Technologies Co., Ltd., Annual General Meeting, May 12, 2022

Recent updates

Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) Looks Just Right With A 38% Price Jump

Full year 2023 earnings: EPS misses analyst expectations

Medprin Regenerative Medical Technologies Co., Ltd., Annual General Meeting, May 10, 2024

Investor sentiment deteriorates as stock falls 18%

Medprin Regenerative Medical Technologies Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Medprin Regenerative Medical Technologies Co., Ltd. (SZSE:301033) announces an Equity Buyback for CNY 20 million worth of its shares.

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Medprin Regenerative Medical Technologies Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Medprin Regenerative Medical Technologies Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.21 in 2Q 2022)

New minor risk - Dividend sustainability

Medprin Regenerative Medical Technologies Co., Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Medprin Regenerative Medical Technologies Co., Ltd. Approves Cash Dividend for the Year 2022

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 2Q 2021)

Investor sentiment improved over the past week

Medprin Regenerative Medical Technologies Co., Ltd., Annual General Meeting, May 12, 2022

Medprin Regenerative Medical Technologies Co., Ltd. Announces Profit Distribution for 2021

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.21 in 1Q 2021)

Investor sentiment deteriorated over the past week

CEO

Permanencia

Compensación